INTRODUCTION
Greater fruit and vegetable intake is recommended to prevent cancer generally, but it is unknown if it protects against prostate cancer specifically. A comprehensive review on nutrition, food, and prostate cancer was published in 1997 by the World Cancer Research Fund and the American Institute for Cancer Research titled Food, Nutrition, and the Prevention of Cancer: a Global Perspective (1) (hereafter referred to as the 1997 Global Review). This report will summarize briefly the conclusions from that review on fruits and vegetables and their major nutrients and phytochemicals, discuss major studies published since 1997, and a few earlier studies not mentioned in the 1997 Global Review, and suggest directions for future research.
CAROTENOIDS
Carotenoids may be beneficial for several different cancer sites, including the prostate gland. One proposed anticancer mechanism is based on vitamin A, which we receive from animal sources in the form of retinol and from fruits and vegetables in the form of carotenoids, some of which have provitamin A properties. Epithelial tissues rely on retinoids for normal cellular differentiation. In addition, many carotenoids have antioxidant capabilities that could protect against free-radical damage to DNA (2) . While some evidence from experimental studies supports a role for vitamin A (3-6) and carotenoids (7) (8) (9) to protect against development of prostate cancer, results from epidemiologic studies have been ambiguous. The conclusion of the 1997 Global Review was that no judgement was possible given the inconsistent nature of study results. Since the publication of that report, two clinical trials (10-12), a dietary cohort study (13), 12 case-control studies (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) , and three prospective serum studies (26) (27) (28) (29) have examined the relation between carotenoids and prostate cancer.
Of the 12 recent case-control studies, only three reported statistically significant relative risks for specific carotenoids (21, 22, 25) , and one of these was a positive association (21) . Oishi et al. (25) observed a relative risk of 2.13 (95 percent confidence interval (CI): 1.20, 3.77) for low versus high intakes of (3-carotene. Jain et al. (21) reported an elevated risk of prostate cancer associated with greater cryptoxanthin intake (relative risk (RR) = 1.44, p = 0.03), while Cohen et al. (22) found a borderline statistically significant 32 percent decreased multivariate relative risk for higher intakes of lutein plus zeaxanthin (p = 0.09). A cohort study among 1,900 Western Electric workers in Chicago observed no association for dietary intake of P-carotene and prostate cancer risk (13) .
The Physicians' Health Study investigated P-carotene supplementation (50 mg on alternate days) with cancer and cardiovascular disease among 22,000 US physicians in a randomized clinical trial and found no association with prostate cancer (11) . However, low versus high baseline serum measures of P-carotene was associated with a 45 percent increase in prostate cancer risk (p = 0.06). Among men with low baseline plasma P-carotene levels, P-carotene supplementation was inversely associated with prostate cancer incidence over 12 years of randomized treatment (RR = 0.68, p = 0.04) (10) . Baseline plasma a-carotene, Pcryptoxanthin, and lutein levels were not associated with prostate cancer risk during 13 years of follow-up, while baseline plasma lycopene was associated with a 44 percent reduction in risk (RR = 0.56 comparing highest with lowest quintiles, p = 0.05) (27) . Interestingly, this reduction in risk was only evident among men on placebo. Men receiving Pcarotene supplementation had a lower risk of prostate cancer compared with men on placebo only if they had low plasma lycopene or plasma P-carotene levels, suggesting a ceiling on the achievable benefits of high dietary lycopene intake or P-carotene supplementation (10, 27) .
In the Alpha-Tocopherol Beta-Carotene Cancer Prevention Trial, 29,133 Finnish male smokers were randomized to either 50 IU of a-tocopherol, 20 mg of P-carotene, both, or placebo. After a median follow-up of 6.1 years, the investigators reported that men receiving p-carotene supplementation experienced a statistically significant elevation in stages n-IV prostate cancer incidence (RR = 1.35, 95 percent CI: 1.01,1.80) (12) .
Eichholzer et al. (28) reported no association between serum carotene and risk of fatal prostate cancer in a Swiss population with 17 years of follow-up. Nomura et al. (26) examined serum levels of total carotene, as well as lutein, lycopene, a-and (3-carotene, zeaxanthin, and p-cryptoxanthin among Japanese-Americans in Hawaii and observed no association with prostate cancer risk.
Lycopene has recently been reviewed extensively for its potential anticarcinogenic properties in several organs, including the prostate gland (30) . Lycopene, which is not converted to vitamin A, is the most potent quencher of single oxygen among the carotenoids (31) , is a powerful trapper of nitrogen oxide species (32) , and suggestive in vitro data support a role for lycopene in suppressing the growth of prostate cancer (30) . Dietary lycopene intake has been studied in two cohort (33, 34) and six case-control (18, (20) (21) (22) (23) (24) studies (including studies mentioned in the 1997 Global Review). Of these, only the Health Professionals Follow-up Study observed a statistically significant inverse association between risk of prostate cancer and lycopene intake (33) . Two (27, 35) out of three (26, 27, 35) serum studies on plasma lycopene and prostate cancer risk have observed inverse associations, although only the Physicians' Health Study was statistically significant (27) . Tomato products, which are by far the major source of lycopene in our diets, have also been studied specifically with regard to prostate cancer (see the section on Vegetables below).
In conclusion, most epidemiologic studies suggest no association for total carotenoids, but further research is warranted on the potential beneficial effects of P-carotene, lutein, zeaxanthin, lycopene, and on potential interactions among these nutrients.
VITAMIN E
Vitamin E has been hypothesized to protect against chronic disease via its strong antioxidant properties and positive effects on immune function (36, 37) . The experimental evidence that vitamin E can suppress cancer growth has been reviewed in detail elsewhere (38) . Israel et al. (39) recently demonstrated that vitamin E succinate can induce apoptosis in LnCaP cells, but not in normal prostate cells. Vitamin E refers to several compounds-a-, p-, y-, and 5-tocopherol, and the tocotrienols. Human diets predominantly contain a-tocopherol, which is the most potent tocopherol biologically (40) . However, some recent evidence suggests a role for ytocopherol in protecting against prostate cancer (41, 42) . y-Tocopherol is also a potent trapper of nitrogen oxide species (32) .
The 1997 Global Review summarized three epidemiologic studies (35, 43, 44) on vitamin E and prostate cancer risk and concluded that no judgement was possible given the limited evidence. One of these studies found no association for vitamin E intake (43); the other two studies observed suggestive but not statistically significant inverse associations for serum vitamin E and prostate cancer risk (35, 44) , although in one study this was only among men younger than age 70 years (35) .
Since that report, two cohort (45, 46) and four casecontrol (16, 18, 21, 24 ) studies observed no association for dietary or supplemental vitamin E intake (18, 46) and prostate cancer risk. In contrast, three case-control studies from distinct countries (Serbia, Greece, and Uruguay) observed inverse associations between dietary vitamin E and prostate cancer risk (19, 20, 47) , with statistically significant reductions of 40 percent or greater.
The most provocative evidence for a protective effect of vitamin E on prostate cancer risk comes from the AlphaTocopherol Beta-Carotene Cancer Prevention Trial (12) . The investigators observed an approximate statistically significant 40 percent reduction in prostate cancer incidence and mortality among men receiving 50 mg (equivalent to 50 IU) supplements of a-tocopherol daily. In the Health Physicians' Follow-up Study, null associations were observed for total, advanced, and fatal prostate cancer and self-reported vitamin E supplement intake (46), but there was a borderline statistically significant relative risk of 0.5 for metastatic and fatal prostate cancer among smokers.
Studies on circulating vitamin E and total prostate cancer not mentioned in the 1997 Global Review have generally not shown a clear association (26) (27) (28) 45) , while two studies that stratified on smoking observed statistically significant inverse associations for plasma vitamin E levels and risk of advanced (27) and fatal (28) prostate cancer only among smokers. In addition, the Alpha-Tocopherol Beta-Carotene Cancer Prevention Trial was conducted exclusively among smokers, and the apparent benefit of vitamin E was considerably stronger in longer-term and heavier smokers (12) . Smoking may be more of a risk factor for fatal (48-51) rather than total (52-58) prostate cancer, suggesting that it promotes the development of more aggressive or metastatic tumors. The hypothesis that vitamin E specifically counteracts the adverse promoting effect of smoking, but is less beneficial among nonsmokers, warrants further research.
VITAMIN C
Vitamin C, or ascorbic acid, may reduce damage to cells by neutralizing toxic oxygen radicals, thereby protecting the body against aging and chronic diseases such as cancer (59) . In contrast, recent experimental studies suggest that vitamin C may inhibit the growth of androgenindependent prostate cancer cells in vitro by creating reactive oxygen species that kill the tumor cells (60, 61) . Vitamin C and vitamin K3 combinations are toxic to DU145 prostate cancer cells in vitro (62) , suggesting therapeutic implications (60, 61) .
Again, however, while the experimental evidence is intriguing, the conclusion of the 1997 Global Review was that high dietary vitamin C intake had no relation to prostate cancer risk. Of relevant studies not included in the previous report, two of two cohort (13, 63) , one of one prospective serum (28) , and 11 of 12 case-control (14, (16) (17) (18) (19) 21, 22, 24, 25, 64, 65) studies reported no association for vitamin C and prostate cancer risk. To our knowledge, only one study recently reported a statistically significant decreased risk of prostate cancer associated with high vitamin C intake (RR = 0.40, p = 0.008) (20) . Thus, we conclude that vitamin C is unlikely to affect prostate cancer risk.
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FRUITS
The conclusion of the 1997 Global Review for fruits and prostate cancer risk was that results were "markedly inconsistent" and no judgement was possible. Studies published more recently have shed little additional light on this topic. Two large cohort studies conducted in Hawaii (66) and Finland (34) observed no association for total fruits. In contrast, The Netherlands Cohort Study reported statistically significant positive linear trends for greater total (p = 0.02) and citrus (p = 0.01) fruit intake and prostate cancer risk (67) , and a case-control study conducted among 156 cases in Uruguay observed a 70 percent elevation in prostate cancer risk with greater fruit intake (p = 0.04) (68). Of eight additional case-control studies, one observed a borderline statistically significant 45 percent increase for citrus fruits (18) , one reported a statistically significant 50 percent increase for total, citrus, and non-citrus fruits (21) , two observed borderline inverse associations (20, 69) (though one reported this among white but not black men), and four reported null associations for various measures of fruit intake (14, 22, 47, 70) .
Thus, we conclude that fruit intake is not substantially related to risk of prostate cancer, and if anything, may be associated with a slightly elevated risk.
VEGETABLES
A wide variety of vegetables have been examined in association with prostate cancer risk in diverse ethnic populations, and the 1997 Global Review concluded that diets high in vegetable intake could possibly decrease risk of prostate cancer; in the least, there is little evidence of any detrimental effect. Specific and total vegetables have been statistically significantly inversely associated with prostate cancer risk in one cohort (67) and seven case-control (18, 20-22, 47, 69 , 71) studies not mentioned in the previous report. In contrast, two cohort (34, 66) and six case-control (23, 68, 70, 72-74) studies observed no association between various vegetable categories and prostate cancer risk.
Individual studies have categorized vegetables in various ways, making general conclusions about specific vegetables challenging. While results are mixed, it appears that beans, legumes, pulses and nuts (18, 21, 22, 67, 75) , carrots (22, 76) , green leafy (21, 71, 76) , and possibly cruciferous (22, 76) vegetables may offer some protection against prostate cancer.
Tomatoes or tomato products have been associated with 15-50 percent reductions in prostate cancer risk in two cohort (33, 75) and three case-control (21, 47, 69) studies, while null associations were reported in two cohort (48, 67) and two case-control (22, 23) studies. The current literature regarding tomatoes and cancer risk was recently reviewed in detail (30) .
We conclude that there is reasonable though mixed evidence for an inverse association between prostate cancer risk and vegetables, including tomatoes, legumes, and beans.
CONCLUSIONS
Fruits are unlikely to substantially influence prostate cancer risk, while vegetables and their associated nutrients and phytochemicals may have anti-prostate cancer properties. Each of these, however, requires further study, and several biologic and methodological issues should be considered.
Firstly, there may be biologic interaction among nutrients and phytochemicals. Some tocopherols and carotenoids may protect against similar reactive chemical species; thus, the relative roles of each may differ in populations depending on their average levels. Secondly, some factors may be important in the context of other exposures, such as vitamin E among smokers. Thirdly, varying diagnostic and screening technologies may cause substantial biologic heterogeneity in prostate cancer across studies; the impact of a factor may be different for early-stage prostate-specific antigendetected tumors versus aggressive fatal cancers.
Vegetables are a complex entity, and variations in followup time, study design (retrospective versus prospective), and the comprehensiveness of questionnaires may influence results. Randomized intervention trials may be appropriate to examine the most promising nutrients and phytochemicals, but even these studies may yield conflicting results due to varying doses, follow-up times, or issues of biologic complexity, such as presence or absence of modifying cofactors. In conclusion, we recommend additional studies on specific vegetables, micronutrients, and prostate cancer, with careful consideration of the above issues.
